Figure 3.
Figure 3. IRBP and S-Ag receptor crosstalk. (A) IRBP and S-Ag share a common chemoattractant receptor. Monocyte-derived iDCs were subjected to cross-desensitization analysis. Pretreating iDCs with 100 ng/mL IRBP (▨) inhibited iDC migration to both IRBP and S-Ag. In contrast, pretreating iDCs with 100 ng/mL of S-Ag (▦) only inhibited iDC migration to S-Ag. (B) IRBP and S-Ag desensitize iDC migration to CXCL11 (ITAC). Pretreating iDCs with 100 ng/mL IRBP (▨) or 100 ng/mL of S-Ag (▦) inhibited iDC migration to CXCL11. (C) IRBP desensitizes iDC migration to CXCL13 (BCA-1). Pretreating iDCs with 100 ng/mL IRBP (▨) inhibited iDC migration to CXCL13. *StatView Student t with P ≤ .0001 for maximum chemotactic responses vs “0” control; **P ≤ .005. Inhibited chemotaxis that was not significantly different from media control (□) was noted with #. n = 3. Representative experiments are shown. Error bars indicate standard deviation.

IRBP and S-Ag receptor crosstalk. (A) IRBP and S-Ag share a common chemoattractant receptor. Monocyte-derived iDCs were subjected to cross-desensitization analysis. Pretreating iDCs with 100 ng/mL IRBP (▨) inhibited iDC migration to both IRBP and S-Ag. In contrast, pretreating iDCs with 100 ng/mL of S-Ag (▦) only inhibited iDC migration to S-Ag. (B) IRBP and S-Ag desensitize iDC migration to CXCL11 (ITAC). Pretreating iDCs with 100 ng/mL IRBP (▨) or 100 ng/mL of S-Ag (▦) inhibited iDC migration to CXCL11. (C) IRBP desensitizes iDC migration to CXCL13 (BCA-1). Pretreating iDCs with 100 ng/mL IRBP (▨) inhibited iDC migration to CXCL13. *StatView Student t with P ≤ .0001 for maximum chemotactic responses vs “0” control; **P ≤ .005. Inhibited chemotaxis that was not significantly different from media control (□) was noted with #. n = 3. Representative experiments are shown. Error bars indicate standard deviation.

Close Modal

or Create an Account

Close Modal
Close Modal